-
1 Comment
IRIDEX Corporation is currently in a long term uptrend where the price is trading 34.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 2.7.
IRIDEX Corporation's total revenue rose by 209.0% to $36M since the same quarter in the previous year.
Its net income has increased by 99.6% to $-6K since the same quarter in the previous year.
Finally, its free cash flow fell by 1636.5% to $-3M since the same quarter in the previous year.
Based on the above factors, IRIDEX Corporation gets an overall score of 4/5.
Sector | Healthcare |
---|---|
Exchange | NASDAQ |
CurrencyCode | USD |
ISIN | US4626841013 |
Industry | Medical Devices |
PE Ratio | None |
---|---|
Market Cap | 20M |
Target Price | 2 |
Beta | 0.74 |
Dividend Yield | None |
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx, a laser photocoagulation system that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments. The company also provides delivery devices, including slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform transscleral laser therapy; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products are used for endophotocoagulation. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company operates in the United States, Europe, the Middle East, Africa, the Asia/Pacific region, and the Americas. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IRIX using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025